|
Several pharmaceutical and biotech
companies are outsourcing their pharmacovigilance
needs due to a variety of reasons. At the smaller companies it could be that
there’s no in-house support. For others the reason could be that there is no
time to find additional resources or to simply increase the power of their
department if the situation calls for it.
For smaller companies, the ones that
have no expert knowledge in the drug safety area, it could be convenient to
select a service provider that has the ability to transfer knowledge based on
their expertise in clinical trials. An effective collaboration of the companies
could be the result. The needs of both have to be specified explicitly and the
service provider would have a leading role.
In case a company
already has a safety surveillance service and needs a boost in power, often the
size
and composition of the team where it is outsourced to becomes more important. A
large team of up-to-date physicians, who understand and are familiar with the
differing country requirements, could provide this extra thrust.
| 
